Progression of cerebral amyloid angiopathy: a pathophysiological framework
- PMID: 37236210
- DOI: 10.1016/S1474-4422(23)00114-X
Progression of cerebral amyloid angiopathy: a pathophysiological framework
Abstract
Cerebral amyloid angiopathy, which is defined by cerebrovascular deposition of amyloid β, is a common age-related small vessel pathology associated with intracerebral haemorrhage and cognitive impairment. Based on complementary lines of evidence from in vivo studies of individuals with hereditary, sporadic, and iatrogenic forms of cerebral amyloid angiopathy, histopathological analyses of affected brains, and experimental studies in transgenic mouse models, we present a framework and timeline for the progression of cerebral amyloid angiopathy from subclinical pathology to the clinical manifestation of the disease. Key stages that appear to evolve sequentially over two to three decades are (stage one) initial vascular amyloid deposition, (stage two) alteration of cerebrovascular physiology, (stage three) non-haemorrhagic brain injury, and (stage four) appearance of haemorrhagic brain lesions. This timeline of stages and the mechanistic processes that link them have substantial implications for identifying disease-modifying interventions for cerebral amyloid angiopathy and potentially for other cerebral small vessel diseases.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests EAK reports funding from the Dutch CAA Foundation, Dutch Alzheimer Foundation, Dutch Heart Foundation, and KNAW van Leersum. SJvV reports funding from Therini Bio. MJPvO reports funding to his institution from Alnylam and Biogen, research funding from Phillips, and an unpaid leadership role for ISMRM study group on Neurofluids. MAAvW reports funding to her institution from Alnylam and Biogen. HRS reports funding to his institution from Alnylam and Biogen and lecture honoraria for ACNEM practitioners. ZS reports funding from the Alzheimer's society of Canada. MAvB reports funding to his institution from Alnylam and Biogen and research funding from Phillips. GMT reports funding to her institution from Alynlam and Biogen. EES reports consulting fees from Eli Lilly. DJW reports consulting fees from Alnylam and NovoNordisk; honoraria from NovoNordisk, Bayer, and Alexion; and unpaid leadership roles with the National Institute for Health and Care Excellence and the British & Irish Association of Stroke Physicians. MJHW reports funding to her institution from Alynlam and Biogen. SMG reports support from the Frechette Foundation and an unpaid leadership role for the International CAA Association.
Comment in
-
Implications of a pathophysiological framework for cerebral amyloid angiopathy.Lancet Neurol. 2023 Jul;22(7):550-551. doi: 10.1016/S1474-4422(23)00196-5. Epub 2023 May 23. Lancet Neurol. 2023. PMID: 37236208 No abstract available.
Similar articles
-
Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.Neuropathol Appl Neurobiol. 2022 Apr;48(3):e12782. doi: 10.1111/nan.12782. Epub 2022 Feb 2. Neuropathol Appl Neurobiol. 2022. PMID: 34823269
-
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy.Mol Neurodegener. 2023 Mar 16;18(1):17. doi: 10.1186/s13024-023-00610-x. Mol Neurodegener. 2023. PMID: 36922879 Free PMC article.
-
Vasomotion loss precedes impaired cerebrovascular reactivity and microbleeds in cerebral amyloid angiopathy.Brain Commun. 2025 May 14;7(3):fcaf186. doi: 10.1093/braincomms/fcaf186. eCollection 2025. Brain Commun. 2025. PMID: 40406166 Free PMC article.
-
Cardiovascular Management in Asymptomatic (Silent) Cerebral Microbleeds and Suspected Cerebral Amyloid Angiopathy.Stroke. 2024 Apr;55(4):1101-1112. doi: 10.1161/STROKEAHA.123.044167. Epub 2024 Mar 11. Stroke. 2024. PMID: 38465605 Review.
-
Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy.Acta Neuropathol Commun. 2024 Jun 24;12(1):103. doi: 10.1186/s40478-024-01823-x. Acta Neuropathol Commun. 2024. PMID: 38915119 Free PMC article.
Cited by
-
Neurovascular coupling in early stage dementia - A case-control study.J Cereb Blood Flow Metab. 2024 Jun;44(6):1013-1023. doi: 10.1177/0271678X231214102. Epub 2023 Nov 22. J Cereb Blood Flow Metab. 2024. PMID: 37994030 Free PMC article.
-
Exploration of common pathogenic genes between cerebral amyloid angiopathy and insomnia based on bioinformatics and experimental validation.Sci Rep. 2025 Jul 20;15(1):26365. doi: 10.1038/s41598-025-12553-y. Sci Rep. 2025. PMID: 40685483 Free PMC article.
-
Targeting lysyl-oxidase (LOX) may facilitate intramural periarterial drainage for the treatment of Alzheimer's disease.Cereb Circ Cogn Behav. 2023 Jun 23;5:100171. doi: 10.1016/j.cccb.2023.100171. eCollection 2023. Cereb Circ Cogn Behav. 2023. PMID: 37457664 Free PMC article. Review.
-
Acquired cerebral amyloid angiopathy: more questions than answers.Eur J Neurol. 2024 Jun;31(6):e16299. doi: 10.1111/ene.16299. Epub 2024 Apr 10. Eur J Neurol. 2024. PMID: 38597136 Free PMC article. No abstract available.
-
Is CAA a perivascular brain clearance disease? A discussion of the evidence to date and outlook for future studies.Cell Mol Life Sci. 2024 May 27;81(1):239. doi: 10.1007/s00018-024-05277-1. Cell Mol Life Sci. 2024. PMID: 38801464 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources